Seattle Genetics and Bayer Partner for a Second Time to Develop Antibody-Drug Conjugates
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 7 (Table of Contents)
Published: 6 Jul-2013
DOI: 10.3833/pdr.v2013.i7.1962 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Bayer has formed a second antibody-drug conjugate (ADC) collaboration with Seattle Genetics under which it will obtain worldwide rights to utilise the company’s auristatin-based ADC technology with antibodies to several undisclosed cancer targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS